Research Article
Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
Table 1
Baseline characteristics of the study population.
| | Parameter | OPT group | Control group | value |
| | Age (mean ± SD) | 30.57 ± 5 | 32.76 ± 7.09 | 0.207 | | Gender ratio (female/male) | 19/9 | 16/12 | 0.687 | | Disease duration | 2.60 ± 1.96 | 4.67 ± 4.48 | 0.174 | | DMDs before relapse n (%) | | | | | Glatiramer acetate | 1 | 5 | .084 | | Interferon beta 1b | 0 | 1 | 1.000 | | Interferon beta 1a | 8 | 6 | 0.537 | | Dimethyl fumarate | 1 | 2 | 0.553 | | Fingolimod | 2 | 1 | 0.553 | | No previous use of DMDs | 16 | 13 | 0.422 | | EDSS (mean ± SD) | 3.21 ± 1.40 | 3.28 ± 1.13 | 0.834 | | Marital status (married) | 53.6% | 71.4% | 0.626 | | Urinary tract symptoms, n (%) | 12 (42.9%) | 8 (28.6%) | 0.033 |
|
|
MS: multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; OPT: oral prednisone taper; SD: standard deviation; DMDs: Disease-Modifying Drugs; EDSS: Expanded Disability Status Scale.
|
